{"id":17915,"date":"2014-04-24T01:30:00","date_gmt":"2014-04-23T23:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/rapporto-cesbio-13-spesa-ssn-e-per-farmaci-biotech\/"},"modified":"2014-04-24T01:30:00","modified_gmt":"2014-04-23T23:30:00","slug":"rapporto-cesbio-13-spesa-ssn-e-per-farmaci-biotech","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/rapporto-cesbio-13-spesa-ssn-e-per-farmaci-biotech\/","title":{"rendered":"CeSBio report, 13% NHS expenditure is for biotech drugs"},"content":{"rendered":"

        \"\"<\/font><\/span><\/p>\n

Expenditure on biotechnological drugs reached 3.6 billion euros in Italy in 2013, equal to 12.9% of the total pharmaceutical expenditure paid by the NHS and 34.5% of expenditure on medicines purchased by health facilities, and a rate of growth, with reference to the latter, in line with the general market trend. <\/p>\n

<\/font><\/span><\/p>\n

This is what emerges from the first report by CeSBio (Centre for studies and research on healthcare biotechnology and the biotech sector) born from the collaboration between the Research center on healthcare and social assistance management (Cergas) of Bocconi University, the Department of drug from the University of Eastern Piedmont and the Italian Association for the Development of Biotechnology (Assobiotec). <\/p>\n

<\/font><\/span><\/p>\n

The first report, based for the quantitative part on Ims Health data, is dedicated to biotechnological drugs and to national and regional policies for their government. As far as biosimilar drugs are concerned, these have seen a significant increase in their market share in volumes and values, reaching overall, in 2013, 28.3% of the reference market (molecules with expired patents) in volumes (1.3% in 2009 ) and 24.1% as expenditure (1.3% in 2009).<\/p>\n

<\/font><\/span><\/p>\n

Barbara Di Chiara \u2013 April 24, 2014 \u2013 <\/span><\/i>PharmaKronos<\/p>\n

<\/i><\/span><\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

          La spesa per farmaci biotecnologici ha raggiunto nel 2013 in Italia i 3,6 miliardi di euro, pari al 12,9% della spesa farmaceutica complessiva a carico del Ssn e il 34,5% della spesa per medicinali acquistati dalle strutture sanitarie, e un tasso di crescita, con riferimento a questi ultimi, in linea con l’andamento generale di …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-17915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=17915"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/17915\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=17915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=17915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=17915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}